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Abstract
Background:  Breast carcinoma is a disease with a tremendous heterogeneity in its clinical
behavior. Newer prognostic factors and predictors of response to therapy are needed. The aim of
this study was to evaluate the expression of HER-2, estrogen receptor (ER) and progesterone
receptors (PR) in breast carcinoma and to compare it with other prognostic parameters such as
histological type and grade, tumor size, patients' age, and lymph node metastases.
Patients and methods: This is a retrospective study conducted in the department of pathology
at Sfax University Hospital. Confirmed 155 Cases of breast carcinoma were reviewed in the period
between January 2000 and December 2004. We used immunohistochemistry to evaluate the
expression of HER-2, ER, and PR receptor and Chi-square and Fisher exact test to correlate
immunohistochemical findings with prognostic parameters for breast carcinoma such as patients'
age, tumor size, histological type, histological grade and lymph node status.
Results: The mean age of patients was 51.5 years, ranging from 22 to 89 years. 80 (51.6%) of the
patients were below 50 years. The percentage of expression of HER-2, ER and PR was 26, 59.4,
and 52.3%, respectively. HER-2 was over-expressed (3+) in 18.1% of the cases, was inversely
related to ER expression (p = 0.00) and to PR expression (p = 0.048). This over-expression was
also associated with a high tumor grade with marginal significance (p = 0.072). A negative
correlation was noted between ER and PR expression and SBR grade (p = 0.000) and ER and age
(p = 0.002).
Conclusion: HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting
female patients. This group presents apparently an aggressive form of breast carcinoma with high
histological grade and negative ER.
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Background
Breast carcinoma is the most common malignant tumor
and the leading cause of carcinoma death in women with
a tremendous heterogeneity in its clinical behavior.
According to data from the Cancer Registry of Tunisia,
breast carcinoma is the most frequent malignant neo-
plasm affecting Tunisian female patients with an inci-
dence of 23.6/100.000 inhabitants [1]. The data of our
registry show that women with breast carcinoma in Tuni-
sia are relatively younger than in Western countries, with
an average age of 51 years [2]. The incidence standardized
on the age of the cancer of the breast in Tunisia was 16.7/
100,000 women) [3]. This may suggest that breast carci-
noma in Tunisia may have some biological features that
need to be explored. Besides, the increasing incidence and
significant breast cancer mortality (Overall survival rate =
50.5% after 5 years) [4] highlight the need for new thera-
peutic development, especially targeted treatment. A
humanized monoclonal antibody, trastuzumab (Hercep-
tin), targeting the human epidermal growth factor recep-
tor 2 (HER-2) gene is a prime example of this new class of
treatment. The (HER-2) gene is localized on chromosome
17q. It encodes for a transmembrane tyrosine kinase
receptor protein that is a member of the HER family. HER-
2 gene amplification is found in 10–34% of invasive
breast carcinomas and is regarded as an important prog-
nostic marker indicating poor patient survival [5]. The
aim of this study was to evaluate the expression of HER-2,
estrogen (ER) and progesterone (PR) receptors in breast
carcinoma and to compare it with other prognostic
parameters such as histological type and grade, tumor
size, patients' age, and lymph node metastases.
Patients and methods
Patients and specimens
In this study, we conducted a comprehensive analysis of
178 breast carcinomas collected in the Sfax University
Hospital between January 2000 and December 2004. Our
study concerned a sample size of 155 because these were
the only cases for which we had complete information
about the patient and the tumor. Also, these were the only
cases whose paraffin blocks had enough tissue to allow
extra sections for our study and eventually for future
examination. In situ carcinomas were not included in this
study.
In fact, invasive breast carcinoma samples were studied
after informed consent and IRB approval from the 155
patients. Patient characteristics are summarized in Table
1. The patients' age ranged from 22 to 89 years (mean age:
51.5 years), 80 (51.6%) patients were less than 50 years
old and 72 (46.4%) were between the ages of 30 and 50.
The tumor size varied from 0.9 cm to 16 cm (mean diam-
eter: 4 cm). It was between 2 and 5 cm in 63.2% of the
cases. The remaining cases had a tumor size more than 5
cm (23.8%) and less than 2 cm (12.9%). The histological
type was determined on tissue sections. The microscopic
grading of Scarff-Bloom-Richardson (SBR) was used: 17
cases were grade 1, 98 cases grade 2 and 40 cases grade 3.
Lymph node involvement was detectable in 65% of cases.
Patients were treated by a multimodality program: All
patients underwent surgical treatment (modified radical
mastectomy: 88 cases; breast conserving surgery: 18 cases;
Mastectomy without axillary clearance: 2 cases). Systemic
therapy, radiotherapy and hormone therapy (tamoxifen)
were received in 92, 76 and 46 cases respectively.
Pathological diagnosis
All surgical tissue specimens were fixed in 10% formalde-
hyde, embedded in paraffin, sectioned and stained with
Hematoxylin/Eosin. According to the WHO classification
[6], there were 130 (83.8%) ductal carcinomas and 25
(16.1%) non ductal carcinomas, subdivided into: 8
Table 1: Clinicopathological features (n = 155)
n%
Age
≤ 45 years 61 39,4
> 45 years 94 60,6
Tumor size
≤ 50 mm 118 76,1
> 50 mm 37 23,9
Tumor grade
11 7 1 1
29 8 6 3 , 2
34 0 2 5 , 8
Histologic type
Ductal 130 83.8
Non ductal 25 16.1
Lymph node
Negative 90 58,1
Positive 65 41,9
ER expression
Negative 63 40,6
Positive 92 59,4
PR expression
Negative 73 47,1
Positive 81 52,3
HER-2 status
Negative (score 0, 1, 2+) 127 81,9
Positive (score 3+) 28 18,1
Surgery
MRM 88* 81.4*
BCS 18* 16.6*
MWAC 2* 1.8*
Systemic therapy 92* 85.1*
Radiotherapy 76* 70.3*
Hormone therapy 46* 42.5*
HER-2: Human epidermal growth factor receptor 2; ER: Estrogen 
receptor; PR: Progesterone receptor; MRM: modified radical 
mastectomy; BCS: breast conserving surgery; MWAC: Mastectomy 
without axillary clearance. *: n = 108.World Journal of Surgical Oncology 2008, 6:112 http://www.wjso.com/content/6/1/112
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(5.8%) inflammatory carcinomas, 6 (3.8%) infiltrating
lobular carcinomas, 5 (3.2%) mucinous carcinomas, 3
(1.9%) endocrine carcinomas, 1 (0.6%) medullary carci-
noma, 1(0.6%) metaplastic carcinoma (carcinosarcoma)
and 1(0.6%) oncocytic carcinoma.
Immuno-histochemical staining
Immuno-staining of the HER-2 protein, estrogen (ER) and
progesterone (PR) receptors was performed for all speci-
mens. Four micrometer sections attached on silanized
slides were de-waxed in xylene, rehydrated in graded eth-
anol and covered with 10 mM citrate buffer (pH 6). They
were then incubated for 30 min with primary monoclonal
antibodies against HER-2 (DAKO, clone 124, 1:100), ER
(DAKO, clone 1D5, 1/25) and PR (DAKO, clone PgR636,
1/50), followed by incubation with biotin-labeled sec-
ondary antibodies. The streptavidin-peroxidase complex
was visualized using di-aminobenzidine as a chromoge-
nic substrate.
All slices were evaluated without knowledge of the clinical
outcome. For each run of staining, a positive control slides
were prepared from breast carcinoma known to be posi-
tive for the proteins studied. A semi quantitative score was
used to record results of ER and PR staining according to
the system established by Allred et al [7].
HER-2 was scored from 0 to 3 scales according to the cri-
teria set by Dako. The staining was scored as negative (0)
when no membrane staining was observed, or when
membrane staining was observed in less than 10% of the
tumor cells, weak positive (1+) if weak focal membrane
staining was seen in more than 10% of the tumor cells,
intermediate (2+) if weak to moderate, complete mem-
brane staining was seen in more than 10% of the tumor
cells; and strongly positive (3+) if intense and complete
membrane staining with weak to moderate cytoplasmic
reactivity was seen in more than 30% of the tumor cells.
In the final analysis, only score 3 cases were considered as
HER-2 overexpression cases. Fluorescence in situ hybridi-
zation (FISH) was not performed in this study.
Statistical analysis
Statistical analysis was used to evaluate correlations
between expression of HER-2, ER and PR and clinico-
pathological parameters. It was done using the SPSS Inc.
software (Version 13). Relationships between qualitative
parameters were determined using the Chi-square and
Fisher Exact Tests. Statistical significance was defined as p
< 0.05.
Results
Relationships between HER-2, ER and PR expression
The expression rate of HER-2, ER and PR receptors was
respectively 26, 59.4, and 52.3% (figure 1). HER2 was
over expressed (3+) in 28 (18.1%) cases (figure 2). Simul-
taneous negative expression of ER, PR and HER-2 was
found in 34 cases (21.9%). Conversely, Simultaneous
expression of ER, PR and over expression of HER-2 was
found in only 5 cases (3.2%). The percentage of HER-2
over-expression was sharply weaker in ER positive tumors:
7.6%, compared with 33.3% for ER negative tumors (p:
0.000). Over-expression of HER-2 was also inversely
related to PR status (p: 0.048) (Table 2). Moreover, we
have found a positive correlation between ER and PR (p =
0.000) (Table 3).
Examples of strong nuclear immunostaining with hormonal receptors Figure 1
Examples of strong nuclear immunostaining with hormonal receptors. (a) ER+. (b) PR+.World Journal of Surgical Oncology 2008, 6:112 http://www.wjso.com/content/6/1/112
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Relationships between HER-2, ER and PR status and 
clinico-pathological parameters
In the comparative analysis of clinico-pathological
parameters of breast carcinoma and HER-2 expression,
the latter was not correlated with age nor with tumor size.
Among patients with tumor size more than 5 cm (T3),
27% had HER-2 overexpression compared to 15.3% with
tumors less than 5 cm (T1 and T2) (p: 0.104). In contrast,
Patients with ER negative tumors were mostly young (< 30
years and between 30–50 years), as compared to positive
ER expression in patients aged above 55 years. There was
also a strong correlation with lymph node involvement (p
= 0.000). HER-2 overexpression was also correlated with
histological grade with marginal significance: only 14,8%
of grade 1–2 carcinomas were HER-2 over expressed com-
pared to 27.5% with grade 3 carcinoma (p = 0.072). A
negative correlation between ER and PR expression and
histological grade was noted (p = 0.000). There was no
correlation between HER-2 status and histological sub-
type (ductal/non ductal). Inflammatory carcinoma over-
expressed HER-2 in 50% of cases. All cases of mucinous
carcinoma were HER-2 negative. No association was
found between hormonal receptors expression and other
pathological characteristics such as: histological type,
tumor size, and lymph node involvement (Table 4). The
only case of medullary carcinoma was triple negative
(Table 5). Among tumors with ductal carcinoma SBR 1,
only one case was HER-2+.
We have studied the lymph node involvement comparing
ER+PR+HER-2+ with other ERPRHER-2 subgroups; but
we don't found any statically significant correlation
(Table 6).
Discussion
The prognosis of breast carcinomas is related to a large
variety of clinical and pathological factors. It is well
known that ER, PR and HER-2 represent the most accept-
able factors for predicting prognosis response or resistance
to treatment and the potential use of newer drugs [8-11].
The association between Her-2 gene amplification and
poor prognosis was first determined in 1987 by Slamon et
al [12]. In the present study, HER-2 over expression was
seen in 18.1% of Tunisian female patients' breast carcino-
mas. It has been reported that 10–34% of breast carcino-
mas over-express the HER-2 receptor. This characteristic is
associated with more aggressive tumor behavior. The ErbB
receptors themselves regulate estrogen-signaling path-
Microscopy pictures illustrating the patterns of HER-2 immunostaining in breast carcinoma Figure 2
Microscopy pictures illustrating the patterns of HER-2 immunostaining in breast carcinoma. (a) Weak positive 
(1+) pattern exemplified by weak focal membrane staining seen in more than 10% of the tumor cells. (b) Intermediate (2+) pat-
tern, showing weak to moderate complete membrane staining in more than 10% of the tumor cells. (c) Strongly positive (3+) 
pattern shows intense membrane staining with weak cytoplasmic reactivity in more than 30% of the tumor cells.
Table 2: Correlation between HER2 over-expression and 
Hormonal receptors status
Her-2 over-expression
n (%) p
ER 0.000
Positive 7 (7.6)
Negative 21 (33.3)
PR 0.048
Positive 10 (12.34)
Negative 18 (24.65)
ER/PR 0.000
Positive/Positive 5 (7.24)
Negative/Negative 16 (32)
HER-2: Human epidermal growth factor receptor 2; ER: Estrogen 
receptor; PR: Progesterone receptor.
Table 3: Correlation between ER and PR status (P = 0.000)
RP
Negative Positive Total
RE
Negative 50 (79,4%) 13 (20,6%) 63
Positive 23 (25,3%) 68 (74,7%) 91
Total 73 81 154
ER: Estrogen receptor; PR: Progesterone receptorWorld Journal of Surgical Oncology 2008, 6:112 http://www.wjso.com/content/6/1/112
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ways, either by directly phosphorylating the estrogen
receptor, or by activating mitogen-activated protein
kinases, which in turn enhance estrogen receptor signal-
ing [13,14]; furthermore, previous studies of breast cancer
cell lines have implicated growth factor in signaling
repression of PR expression [15].
80 (51.6%) patients were less than 50 years old and 72
(46.4%) of them were between the ages of 30 and 50. In
contrast to what is commonly known about a rising inci-
dence of breast cancer with age, our results showed that
51.6% of the patients examined were young with an age
below 50 years. The mean age of these patients was 51.5,
and 46.4% of them were between the ages of 30 and 50.
This age distribution is significantly younger than what is
currently seen in Western and Arab countries [16,17], and
requires further careful examination to determine the
nature of the predisposing factor(s). One possible expla-
nation is that traditional marriages among first-degree rel-
atives in Tunisia are very common, and, accordingly,
hereditary factors could play a major role. Another factor
could be the degree of obesity associated with a diet high
in fat, carbohydrate, and protein, and lack of exercise,
which have been prevalent in Tunisia the two last decades.
The relative young mean age of our patients may be
explained by the age distribution in our population or by
risk factors that may be particular to our country.
Some authors [18-20] have suggested that HER-2 overex-
pression is associated with young age; our study failed to
reveal a significant relationship between HER-2 overx-
pression and patient's age (women older or younger than
50 years). This may be due to that our report is a small
series.
In contrast, we found that there is a significant association
between the nature of the tumors' expression of ER and
the age of the patients. These results are in agreement with
most reports in the literature which show an association
between the expression of ER and age in breast carcinoma
[18,19,21,22]. However, other studies have found no
Table 4: Correlation of HER-2, ER and PR status with clinicopathological data
HER-2 over-expression ER Positive PR Positive
n (%) p n (%) p n (%) p
Age 0.28 0.002 0. 76
≤ 50 years 17 (21.3) 38 (47.5) 43 (53.8)
> 50 years 11 (14.7) 54 (72) 38 (51.4)
Tumor size 0.104 0.129 0.72
≤ 5 cm 18 (15.3) 74 (62.7) 63 (53.4)
> 5 cm 10 (27) 18 (48.6) 18 (50)
Histologic type 0.33 0.31 0.47
Ductal 22 (16.8) 80 (61.1) 70 (53.8)
Non ductal 6 (25) 12 (50) 11 (45.8)
Lymph-node 0.000 0.88 0.66
Negative 4 (4,4) 53 (58.9) 46 (51.1)
Positive 24 (36.9) 39 (60) 35 (54.7)
Tumor Grade 0.072 0.000 0.000
1–2 17 (14.8) 83 (72.2) 70 (61.4)
3 11 (27.5) 9 (22.5) 11 (27.5)
HER-2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor.
Table 5: Frequency of HER-2, ER and PR expression by histological subtype
Histologic subtype n (%) ER+ (%) PR+ (%) HER2-+ (%)
Ductal NOS 130 (83.3) 61.1 53.8 16.8
Inflammatory 8 (23,5) 37,5 37.5 50
Lobular 6 (17,6) 50 50 16.7
Mucinous 5 (14,7) 60 60 0
Endocrine 3 (8,8) 66.7 33.3 33.3
Metaplastic 1 (2,9) 100 100 0
Medullary 1 (2,9) 0 0 0
Oncocytic 1 (2,9) 0 0 100
NOS: not otherwise specified;HER-2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor.World Journal of Surgical Oncology 2008, 6:112 http://www.wjso.com/content/6/1/112
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association between the age and the degree of expression
of ER by the tumor [23].
In our study, we did not find any significant association
between the age of the patients and their tumor expres-
sion of PR. Similar findings were reported by many
authors [24-26]. Other studies, however, have reported a
higher tumor expression of PR in patients older than 59
years, as compared to those between 50 and 59 years [27].
Our results showed a tendency of HER-2 overexpression
to be more associated with larger tumor size although this
difference was not statistically significant. Similarly, the
fraction of tumors larger than 5 cm tended to have higher
rates of HER-2 overexpression than those below 5 cm in
size (27% versus 15.3%). Several studies have found no
association between Her-2 overexpression and tumor size
[18,28-30]. On the other hand, there was no statistically
significant correlation between hormonal status and size.
This result is in concordance with data reported in the lit-
erature [31,32].
In our study, the most common histological subtypes
were ductal-not otherwise specified (83.8%), followed by
inflammatory carcinoma (5.1%), lobular carcinoma
(3.8%) and mucinous carcinoma (3.8%). Inflammatory
breast carcinoma is particularly common in Tunisia and
the region of North Africa [24]; this confirms the relatively
high percentage of occurrence of this variety in our study.
The highest percentage of HER-2 overexpression (50%)
was seen in inflammatory carcinoma; this support the
view that it known to have an aggressive clinical course,
very often resulting in early recurrence and death. How-
ever, no statistically significant correlation was found
between HER-2 overexpression and histological type
which confirm the data of many reports [33,34]. In con-
trast, recent reports suggest that HER-2 overexpression is
significantly more likely in infiltrating ductal carcinomas
than in infiltrating lobular carcinomas [35]. Our results
show that there was no significant difference between
ductal and lobular carcinoma regarding HER-2 overex-
pression. This could imply that, although lobular carci-
noma is less common than ductal carcinoma, lobular
carcinoma could be equally aggressive. On the other
hand, there was no statistically significant correlation
between hormonal status and histological type which has
also been described in the literature [31,32]. In our study,
some limitations should be considered when interpreting
the results. This study was limited by relatively small num-
bers of non ductal subtypes: endocrine, medullary, meta-
plastic, and oncocytic carcinomas were three or fewer,
resulting in estimates with wide confidence limits.
Most studies have correlated HER-2 overexpression with
poor histological or nuclear grade of the primary tumor
[9-11,28-30,36-38], whereas others have not [39,40].
Traina et al. [41] have demonstrated that only HER-2 (3+)
and histopathologic grading 3 are significantly associated
with overall survival. Similarly, our study showed that
tumors with grade 3 were more often HER-2 negative.
In this study, we also found that lower grade (1–2) of the
tumor was significantly related to the expression of ER
and PR. Similar findings were reported by many studies
[42,31,32].
The prognostic importance of HER-2 has also been ana-
lyzed in the context of patient subgroups with or without
lymph node involvement. Most of the studies that have
examined the prognostic role of HER-2 in patients with
positive lymph nodes have shown that HER-2 amplifica-
tion/overexpression is associated with a worse outcome in
either univariate or multivariate analysis [37,41,43,44].
This finding was also confirmed in our study. A few stud-
ies, however, have not shown statistically significant cor-
relation between HER-2 and lymph node status
[18,28,30].
Despite the great variation in levels of HER-2 positivity,
nearly all investigators report a negative relationship
between HER-2 status and steroid receptors levels [8-
11,15,18,28-30,36-38,41]. Our results confirm this data.
This inverse association has been linked to the fact that
Table 6: Frequency of HER-2 expression for lymph-node status by joint ER/PR expression
No N+
HER-2 HER-2
Negative Positive Total Negative Positive Total
ER- PR- 27(90%) 3 (10%) 30 7 (35%) 13 (65%) 20
ER- PR+ 7 (100%) 0 (0%) 7 1 (16.7%) 5 (83.3%) 6
ER+ PR- 14 (100%) 0(0%) 14 7 (77.8%) 2 (22.2%) 9
ER+ PR+ 38 (97,4%) 1(2.6%) 39 25 (86,2%) 4 (13,8%) 29
Total 86 (95.55) 4(3.45) 90 40 (62.5) 24 (37.5) 64
N0: without lymph node involvement; N+: with lymph node involvement; HER-2: Human epidermal growth factor receptor 2; ER: Estrogen 
receptor; PR: Progesterone receptor.World Journal of Surgical Oncology 2008, 6:112 http://www.wjso.com/content/6/1/112
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estrogens and its receptor are required to suppress HER-2
[13,14]. This leads to lower or absent hormone receptors
in women with HER-2 positive breast cancers. This is one
of the reasons why women who express HER-2 may be
resistant to tamoxifen [45].
Conclusion
Analysis of HER-2 status in breast carcinoma is important
because it provides valuable prognostic, predictive and
therapeutic information. In this study about 155 patients
with infiltrating breast carcinomas, HER-2 overexpression
was evaluated by immunohistochemistry and was
observed in 28 cases (18.1%). Our results showed that
HER-2 over-expression correlates with aggressiveness
parameters such as high histological SBR grade, lymph
node metastases and negative ER/PR status.
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